Piper Sandler analyst Matt O’Brien upgraded Insulet to Overweight from Neutral with a price target of $340, up from $235. The company reported “impressive” Q3 results which exceeded expectations on the top and bottom lines, O’Brien tells investors in a research note. The analyst says O5 as us “capturing meaningfully more share” than he thought, with a specific pickup in competitive wins. He anticipates this will continue in 2023. The momentum in Insulet’s business “is simply too powerful to ignore,” writes O’Brien.
previous post
next post